Yuan A - Search Results

1

Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.

DeNardo G, Yuan A, Goldstein D, Richman C, O'Donnell R, Shen S, Hartmann Siantar C, DeNardo S. DeNardo G, et al. Among authors: yuan a. Cancer Biother Radiopharm. 2003 Apr;18(2):231-7. doi: 10.1089/108497803765036409. Cancer Biother Radiopharm. 2003. PMID: 12804049

2

Application of MINERVA Monte Carlo simulations to targeted radionuclide therapy.

Descalle MA, Hartmann Siantar CL, Dauffy L, Nigg DW, Wemple CA, Yuan A, DeNardo GL. Descalle MA, et al. Among authors: yuan a. Cancer Biother Radiopharm. 2003 Feb;18(1):71-9. doi: 10.1089/108497803321269340. Cancer Biother Radiopharm. 2003. PMID: 12667310

3

Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.

Shen S, DeNardo GL, Yuan A, Hartmann-Siantar C, O'Donnell RT, DeNardo SJ. Shen S, et al. Among authors: yuan a. Cancer Biother Radiopharm. 2005 Dec;20(6):662-70. doi: 10.1089/cbr.2005.20.662. Cancer Biother Radiopharm. 2005. PMID: 16398618

4

Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.

Lehmann J, DeNardo GL, Yuan A, Shen S, O'Donnell RT, Richman CM, DeNardo SJ. Lehmann J, et al. Among authors: yuan a. Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1192-8. doi: 10.1016/j.ijrobp.2006.06.020. Epub 2006 Sep 11. Int J Radiat Oncol Biol Phys. 2006. PMID: 16965873

5

Practical determination of organ S values for individual patients for therapy.

Shen S, DeNardo GL, Macey DJ, O'Donnell RT, Yuan A, DeNardo DA, DeNardo SJ. Shen S, et al. Among authors: yuan a. Nucl Med Biol. 1997 Jul;24(5):447-9. doi: 10.1016/s0969-8051(97)80013-3. Nucl Med Biol. 1997. PMID: 9290081

6

Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies.

Shen S, DeNardo GL, O'Donnell RT, Yuan A, DeNardo DA, DeNardo SJ. Shen S, et al. Among authors: yuan a. Cancer. 1997 Dec 15;80(12 Suppl):2553-7. doi: 10.1002/(sici)1097-0142(19971215)80:12+<2553::aid-cncr30>3.3.co;2-n. Cancer. 1997. PMID: 9406709

7

Imaging for improved prediction of myelotoxicity after radioimmunotherapy.

DeNardo DA, DeNardo GL, O'Donnell RT, Lim SM, Shen S, Yuan A, DeNardo SJ. DeNardo DA, et al. Among authors: yuan a. Cancer. 1997 Dec 15;80(12 Suppl):2558-66. doi: 10.1002/(sici)1097-0142(19971215)80:12+<2558::aid-cncr31>3.3.co;2-5. Cancer. 1997. PMID: 9406710

8

67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.

O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Mirick GR, DeNardo SJ. O'Donnell RT, et al. Among authors: yuan a. Clin Cancer Res. 1999 Oct;5(10 Suppl):3330s-3336s. Clin Cancer Res. 1999. PMID: 10541382 Clinical Trial.

9

A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.

O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Carr CE, Mirick GR, DeNardo SJ. O'Donnell RT, et al. Among authors: yuan a. J Nucl Med. 1999 Dec;40(12):2014-20. J Nucl Med. 1999. PMID: 10616879 Free article. Clinical Trial.

10

Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.

DeNardo GL, O'Donnell RT, Shen S, Kroger LA, Yuan A, Meares CF, Kukis DL, DeNardo SJ. DeNardo GL, et al. Among authors: yuan a. J Nucl Med. 2000 May;41(5):952-8. J Nucl Med. 2000. PMID: 10809213 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

999 results

Search Page

Filters